Navigation Links
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
Date:12/4/2008

First Selective TLR8 Agonist to Advance to Clinical Trials

SAN DIEGO, Dec. 4 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and autoimmune diseases, announced today that it has initiated a Phase I clinical trial of VTX-2337, a selective TLR8 agonist for the treatment of cancer. The multi-center clinical trial is being conducted at the Mayo Clinic Arizona and TGen Drug Development Services (TD2) both in Scottsdale, Arizona.

"We are delighted to advance the first molecule from our Toll-Like Receptor 8 platform, VTX-2337, into the clinic," said Michael Kamdar, Executive Vice President and Chief Business Officer at VentiRx. "This represents a significant milestone for VentiRx and our TLR efforts as we have rapidly advanced into a clinical development company with a novel molecule that may have broad application in the treatment of cancer."

VTX-2337 is a small molecule TLR8 agonist that is expected to be used in combination with standard of care for the treatment of patients with cancer. Preclinical evaluation of VTX-2337 suggests that it may play a key role in augmenting the innate arm of the immune system and provide a valuable addition to various treatment regimens in oncology. The first clinical trial will investigate the safety and pharmacology of multiple doses of VTX-2337 in patients with late stage cancer.

"VTX-2337 is the first selective TLR8 compound to reach the clinic and we are hopeful that modulation of the innate immune response will provide a benefit to patients in a number of oncology indications," said Dr. Robert Hershberg, Executive Vice President and Chief Medical Officer at VentiRx.

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals, Inc. is a biopharmaceutical company committed t
'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... YORK , Sept. 3, 2015 ... glucose device is a home-based electronic device. It ... that transmits information about glucose levels through radiowaves ... is displayed. The regular usage of self-monitoring blood ... prompt an individual to undergo proper diabetes treatment. ...
(Date:9/3/2015)... , Sept. 3, 2015 About dry eye syndrome ... eyes due to deficient tear production or quick tear ... of two types: aqueous tear deficient dry eye and ... lacrimal glands do not produce enough tears, whereas meibomian ... secrete lipids to slow tear evaporation and maintain tear ...
(Date:9/3/2015)... VIEJO, Calif. , Sept. 3, 2015 /PRNewswire/ ... global pharmaceutical company, and AqueSys, Inc. a private ... ocular implants that reduce intraocular pressure (IOP) associated ... into an agreement under which Allergan will acquire ... of the agreement, Allergan will acquire AqueSys for ...
Breaking Medicine Technology:Global Self-monitoring Blood Glucose Devices Market 2015-2019 2Global Dry Eye Syndrome Market 2015-2019 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6
(Date:9/3/2015)... ... September 03, 2015 , ... E-Volve ... a leading national healthcare solutions organization, to provide electronic medical record (EMR) consulting ... agreement, Amerinet members will receive negotiated pricing on E-Volve Health’s Epic EMR consulting, ...
(Date:9/3/2015)... Rhinebeck, NY (PRWEB) , ... September 03, 2015 ... ... Kitslaar when he made the company the final destination of his six-month, 10,000 ... , During the trek—which he calls the “Connecting Las Americas” ...
(Date:9/3/2015)... ... September 03, 2015 , ... Results of a ... Healthcare Research and Policy Analysis has found physician leadership development training programs to ... percent of respondents said their organizations conduct some kind of physician leadership development ...
(Date:9/3/2015)... ... September 03, 2015 , ... Hope For The Warriors® is ... Scholarships are awarded two times each year to spouses or caregivers of post-9/11 ... dedicated to restoring a sense of self, restoring the family unit, and restoring ...
(Date:9/3/2015)... ... September 03, 2015 , ... Today, Splashtop announced availability ... as part of the LANDESK One Partner program. Splashtop remote desktop ... mobile user experience in remote access and control:, , ...
Breaking Medicine News(10 mins):Health News:E-Volve Health to Offer EMR Consulting Solutions to Amerinet Members 2Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 2Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 4Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 5Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 6Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:Splashtop Partners with LANDESK to Deliver High Performance Remote Access and Remote Support to and from Mobile Devices and Chromebook 2Health News:Splashtop Partners with LANDESK to Deliver High Performance Remote Access and Remote Support to and from Mobile Devices and Chromebook 3Health News:Splashtop Partners with LANDESK to Deliver High Performance Remote Access and Remote Support to and from Mobile Devices and Chromebook 4
... Boston, MA--Researchers from Boston Medical Centers (BMC) New ... proportion of their centenarian subjects, avoiding age-related diseases ... the key to their longevity; rather, the avoidance ... their exceptional survival. These findings appear in the ...
... DIEGO, Feb. 11 SpectraScience, Inc. (OTC,Bulltetin ... devices company, today,announced that it has retained ... consulting firm to provide strategic investor relations,services., ... SpectraScience, stated, "We,have selected Hayden Communications because ...
... Funding Totals $60,000; Emergency Call Center Activated ... to Support ... the corporate philanthropy organization of AT&T Inc. (NYSE: T ... In further support of the victims of this disaster, AT&T ...
... new thin-film coating developed at MIT can deliver controlled ... implantation, essentially serving as a micro pharmacy. , The ... cancer, epilepsy, diabetes and other diseases. It is among ... by applying a small electric field. , You can ...
... (Nasdaq:,ICAD), an industry-leading provider of Computer-Aided Detection (CAD),solutions ... that the,Company,s fourth quarter and year end 2007 ... Thursday, March 6, 2008. iCAD management,will discuss the ... am,ET., Shareholders and other interested parties may ...
... Conversion of Shelled Space an Integral Part of MedCath,s ... Corporation,(Nasdaq: MDTH ) and its physician partners today ... TexSAn Heart Hospital, San Antonio, Texas,creating a 120-bed acute ... approximately 36,130 square feet of shelled,space into 60 inpatient ...
Cached Medicine News:Health News:Researchers at BMC find disability does not necessarily follow disease in living to old age 2Health News:SpectraScience, Inc. Retains Hayden Communications 2Health News:AT&T Tennessee Supports Local Disaster Relief Efforts 2Health News:AT&T Tennessee Supports Local Disaster Relief Efforts 3Health News:MIT develops thin-film 'micro pharmacy' 2Health News:iCAD To Release Fourth Quarter and Year End 2007 Financial Results on Thursday, March 6, 2008 2Health News:iCAD To Release Fourth Quarter and Year End 2007 Financial Results on Thursday, March 6, 2008 3Health News:MedCath Plans 60-bed Expansion at TexSAn Heart Hospital 2Health News:MedCath Plans 60-bed Expansion at TexSAn Heart Hospital 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: